Patents by Inventor Bilha Fischer
Bilha Fischer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220220135Abstract: The invention relates to a novel highly selective and potent NPP1 inhibitors, compositions comprising such, and their use as pharmaceuticals.Type: ApplicationFiled: April 18, 2020Publication date: July 14, 2022Applicants: BAR-ILAN UNIVERSITY, ICHILOV TECH LTD, LAVAL UNIVERSITY, UNIVERSITY OF BONNInventors: Hana Bilha FISCHER, Molhm NASSIR, Vadim ZELIKMAN, Uri Moshe ARAD, Jean SEVIGNY, Christa MULLER
-
Publication number: 20220119349Abstract: The present invention is directed to styryl quinolinium compounds, a process for their synthesis and their use for selective nucleoli staining in cells, preferably in living cells and for imaging rRNA.Type: ApplicationFiled: October 21, 2021Publication date: April 21, 2022Inventors: Bilha FISCHER, Abed Elhady SAADY, Yaron SHAV-TAL, Eli VARON
-
Patent number: 9221868Abstract: The disclosure provides particular uridine di- and tri-phosphate compounds of Formula I, and pharmaceutical compositions thereof. The definitions of variables such as R, Y, B, m, Z1, Z2, and Z3 are as provided in the disclosure. These compounds are useful for treatment of diseases, disorders and conditions modulated by P2Y6 receptors, and particularly for lowering intraocular pressure and thereby treating ocular hypertension and/or glaucoma.Type: GrantFiled: December 1, 2011Date of Patent: December 29, 2015Assignees: BAR-ILAN UNIVERSITY, UNIVERSIDAD COMPLUTENSE DE MADRIDInventors: Bilha Fischer, Jesus Jeronimo Pintor, Shay Elyahu, Tamar Ginsburg-Shmuel
-
Publication number: 20140378408Abstract: Particular nucleoside 5?-phosphorothioate analogues, such as, adenosine or uridine 5?-di- or tri-phosphorothioate analogues in which at least one of the bridging oxygen atoms of the phosphorothioate is replaced by a group such as —CH2— or —CCl2—, and at least one of the non-bridging atoms or negatively-charged atoms of the phosphorothioate is either a sulfur atom or a sulfur ion can be formulated into pharmaceutical compositions. These compounds are useful for treatment of osteoarthritis/calcium pyrophosphate dihydrate (CPPD) deposition disease.Type: ApplicationFiled: September 5, 2014Publication date: December 25, 2014Inventors: Bilha FISCHER, Ortal SHIMON, Yael NADEL, Uri ARAD
-
Publication number: 20130324495Abstract: The invention provides particular uridine di- and tri-phosphate derivatives, and pharmaceutical compositions thereof. These compounds are useful for treatment of diseases, disorders and conditions modulated by P2Y6 receptors, and particularly for lowering intraocular pressure and thereby treating ocular hypertension and/or glaucoma.Type: ApplicationFiled: December 1, 2011Publication date: December 5, 2013Applicants: UNIVERSIDAD COMPLUTENSE DE MADRID, BAR-ILAN UNIVERSITYInventors: Bilha fischer, Jesus Jeronimo Pintor, Shay Elyahu, Tamar Ginsburg-Shmuel
-
Publication number: 20100256086Abstract: The invention provides non-hydrolyzable nucleoside polyphosphate derivatives, e.g., 2MeS-adenosine-?,?-CH2-5?-O-(1-boranotriphosphate), 2MeS-adenosine-?,?-CCl2-5?-O-(1-boranotriphosphate), 2-MeS-adenosine-5?-dichloro methylene-diphosphate, 2-MeS-adenosine-5?-difluoromethylene-diphosphate and 2MeS-adenosine-5?-O-(1-boranodiphosphate), as well as pharmaceutical compositions thereof. These compounds are useful for prevention or treatment of diseases or disorders modulated by P2Y-receptors such as type 2 diabetes, and for pain control.Type: ApplicationFiled: November 23, 2008Publication date: October 7, 2010Applicant: BAR-ILAN UNIVETRSITYInventor: Bilha FISCHER
-
Patent number: 7385051Abstract: The invention relates to fluorescent N2,N3-etheno-purine (2?-deoxy) riboside derivatives and fluorescent oligonucleotide probes comprising one or more moieties thereof, their preparation and uses thereof for staining DNA/RNA and for detection and quantitation of genetic material.Type: GrantFiled: January 24, 2006Date of Patent: June 10, 2008Assignee: Bar-llan UniversityInventors: Bilha Fischer, Einat Sharon
-
Patent number: 7368439Abstract: The present invention provides dinucleoside boranophosphate derivatives of the general formula I: wherein X and X? each independently is an unsubstituted or substituted purine or pyrimidine residue; Y and Y? each independently is H or OH; Z1 to Z5 each independently is O? or BH3?, but excluding the compounds wherein Z1 to Z5 are each O?; W1 to W4 each independently is O, CH2, NH or C(Halogen)2; n and n? each independently is 0 or 1; m is 3, 4 or 5; and M+ represents a pharmaceutically acceptable cation, and to pharmaceutical compositions thereof. These dinucleoside boranophosphates are useful for prevention or treatment of diseases or disorders modulated by P2Y receptors such as type 2 diabetes, cystic fibrosis and cancer.Type: GrantFiled: June 14, 2006Date of Patent: May 6, 2008Assignee: BAR - ILAN UniversityInventors: Bilha Fischer, Victoria Nahum
-
Patent number: 7338669Abstract: The invention provides novel inorganic boranophosphate salts that can be used as fertilizers, in detergent formulations, as additive in melts for the glass industry, in boron neutron-capture therapy of cancer, and as synthetic building blocks in the synthesis of boranonucleotides of various lengths.Type: GrantFiled: February 2, 2005Date of Patent: March 4, 2008Assignee: Bar-Ilan UniversityInventors: Bilha Fischer, Victoria Nahum
-
Patent number: 7319093Abstract: 2-Substituted-5?-O-(1-boranotriphosphate)adenosine derivatives having at position 2 a radical R1 selected from the group consisting of H; halogen; O-hydrocarbyl; S-hydrocarbyl; NR3R4; and hydrocarbyl optionally substituted by halogen, CN, SCN, NO2, OR3, SR3 or NR3R4; wherein R3 and R4 are each independently H or hydrocarbyl or R3 and R4 together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic ring optionally containing 1-2 further heteroatoms selected from oxygen, nitrogen and sulfur, and pharmaceutically acceptable salts or diastereoisomers thereof or a mixture of diastereoisomers, are useful for treatment of type 2 diabetes.Type: GrantFiled: October 23, 2002Date of Patent: January 15, 2008Assignees: Bar-Ilan University, University of MontpellierInventors: Bilha Fischer, Victoria Kleiman-Nahum, Pierre Petit
-
Publication number: 20070160682Abstract: The invention provides novel inorganic boranophosphate salts that can be used as fertilizers, in detergent formulations, as additive in melts for the glass industry, in boron neutron-capture therapy of cancer, and as synthetic building blocks in the synthesis of boranonucleotides of various lengths.Type: ApplicationFiled: February 2, 2005Publication date: July 12, 2007Applicant: Barilan UniversityInventors: Bilha Fischer, Victoria Naum
-
Publication number: 20060287271Abstract: Dinucleoside poly(borano)phosphates are provided that can be useful for prevention or treatment of diseases or disorders modulated by P2Y receptors such as type 2 diabetes, cystic fibtosis and cancer.Type: ApplicationFiled: June 14, 2006Publication date: December 21, 2006Applicant: BAR-ILAN UNIVERSITYInventors: Bilha Fischer, Victoria Nahum
-
Publication number: 20060166248Abstract: The invention relates to fluorescent N2,N3-etheno-purine (2?-deoxy) riboside derivatives and fluorescent oligonucleotide probes comprising one or more moieties thereof, their preparation and uses thereof for staining DNA/RNA and for detection and quantitation of genetic material.Type: ApplicationFiled: January 24, 2006Publication date: July 27, 2006Applicant: Bar-Ilan UniversityInventors: Bilha Fischer, Einat Sharon
-
Publication number: 20050065108Abstract: 2-Substituted-5?-O-(1-boranotriphosphate)adenosine derivatives having at position 2 a radical R1 selected from the group consisting of H; halogen; O-hydrocarbyl; S-hydrocarbyl; NR3R4; and hydrocarbyl optionally substituted by halogen, CN, SCN, NO2, OR3, SR3 or NR3R4; wherein R3 and R4 are each independently H or hydrocarbyl or R3 and R4 together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic ring optionally containing 1-2 further heteroatoms selected from oxygen, nitrogen and sulfur, and pharmaceutically acceptable salts or diastereoisomers thereof or a mixture of diastereoisomers, are useful for treatment of type 2 diabetes.Type: ApplicationFiled: November 5, 2004Publication date: March 24, 2005Inventors: Bilha Fischer, Victoria Kleiman-Nahum
-
Publication number: 20040043955Abstract: Ectonucleoside triphosphate diphosphohydrolases [NTPDases; EC 3.6.1.5] constitute a family of enzymes which are involved in the metabolism of extracellular nucleotides, catalysing the hydrolysis of the gamma and beta phosphate bonds of triphospho- and diphosphonucleosides (whereas 5′nucleotidases [EC 3.1.3.5] catalyse the hydrolysis of alpha phosphate bond of monophosphonucleosides). These extracellular nucleotides interact with endothelial, epithelial and smooth muscle cells, as well as blood cells and lymphoid cells, to influence the different physiological systems of vertebrates.Type: ApplicationFiled: July 16, 2003Publication date: March 4, 2004Inventors: Adrien R. Beaudoin, Fernand-Pierre Gendron, Efrat Halbfinger, Bilha Fischer
-
Patent number: 6617439Abstract: C8-substituted purine nucleotide analogs, such as ATP analogs, and their use is described, including their use as inhibitors of NTPDases and thereby as tools to modulate the conversion of nucleotides into nucleoside derivatives, and thus modulate the levels of these compounds. Such modulation further provides for the modulation of the activity and function of many processes which are affected by these compounds.Type: GrantFiled: June 9, 2000Date of Patent: September 9, 2003Assignees: Bar-Ilan University, Universite de SherbrookeInventors: Adrien R. Beaudoin, Fernand-Pierre Gendron, Efrat Halbfinger, Bilha Fischer
-
Patent number: 5861405Abstract: The present invention provides 8-substituted 1,3,7-trialkylxanthines useful as A.sub.2 -selective adenosine receptor antagonists and compositions comprising such compounds. Examples of the 8-substituted 1,3,7-trialkyl xanthines include: ##STR1## In compound (a), R.sub.1, R.sub.3, and R.sub.7 are methyl and X is one to three substituents, which may be the same or different and selected from the group consisting of amino, C.sub.1 -C.sub.4 alkylcarbonylamino, carboxy C.sub.2 -C.sub.4 alkylcarbonylamino, halo, C.sub.1 -C.sub.3 alkyloxy, amino C.sub.1 -C.sub.4 alkyloxy, C.sub.1 -C.sub.4 alkyloxy carbonylamino, amino C.sub.1 -C.sub.4 alkenyloxy, isothiocyanato, and diazonium tetrafluoroborate. In compound (b), R.sub.1, R.sub.3, and R.sub.7 are methyl, R.sub..beta. is hydrogen or methyl, and X is selected from the group consisting of R, C(.dbd.O)OR, and C(.dbd.O)NH--R, wherein R is a C.sub.1 -C.sub.6 alkyl.Type: GrantFiled: November 7, 1994Date of Patent: January 19, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kenneth A. Jacobson, Yishai Karton, Carola Gallo-Rodriguez, Bilha Fischer, Philip J. M. van Galen, Michel Maillard
-
Patent number: 5620676Abstract: The present invention provides certain novel adenosine triphosphate (ATP) analogs, pharmaceutical compositions, and methods of using such analogs in the treatment of septic shock and other disease conditions. Examples of the ATP analogs include the mono-, di- and triphosphates of adenosines with various selected substituents at the 2, 6, 8, and 9-positions, such as alkyl, alkylphenyl, phenylalkyl, S-alkyl, S-alkenyl, S-alkylcyano, S-phenyl, S-alkylphenyl, S-alkylamino, S-alkylthioalkyl, S-alkylthiocyanato, S-alkylaminophenyl, S-alkylnitrophenyl, hydroxy, bromo, fluoro, chloro, and aminoalkylamino. The present invention also provides pharmaceutical compositions of and methods of using certain xanthine and uracil derivatives for the above disease conditions. Examples of the xanthine derivatives include xanthines having alkyl or alkyltriphosphate substituents at the 1, 3, and 7-positions. Examples of the uracil derivatives include 5-fluoro- and 5-bromo uracil triphosphates.Type: GrantFiled: March 31, 1995Date of Patent: April 15, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kenneth A. Jacobson, Bilha Fischer, Michel Maillard